Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Jacksonville, Florida

Phase 3 cancer trials in Jacksonville, FL

62 Phase 3 cancer studies are recruiting participants at sites in Jacksonville as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Jacksonville at a glance

Breast cancer studies recruiting in Jacksonville

Basic details from each study's public record (the 30 most recently updated of 62). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic Hospital ( Site 0013)
    Registry record
    NCT06966700 · updated
  2. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Mayo Clinic - Jacksonville
    Registry record
    NCT05696626 · updated
  3. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study sites
    Cancer Specialists of North Florida · Mayo Clinic Florida
    Registry record
    NCT05633654 · updated
  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Baptist MD Anderson Cancer Center · Baptist Medical Center South · Mayo Clinic in Florida
    Registry record
    NCT05879926 · updated
  5. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Mayo Clinic in Florida
    Registry record
    NCT06748222 · updated
  6. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cancer Specialists of North Florida - Jacksonville
    Registry record
    NCT06790693 · updated
  7. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06380751 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Jacksonville

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Study site
    Cancer Specialists of North Florida
    Registry record
    NCT06875310 · updated
  3. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study site
    Baptist MD Anderson Cancer Center, Baptist Health
    Registry record
    NCT06216301 · updated
  4. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Mayo Clinic in Florida
    Registry record
    NCT07063745 · updated
  5. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    OSE Immunotherapeutics
    Study sites
    Cancer Specialists of North Florida - Northside · Cancer Specialists of North Florida - Riverside · Cancer Specialists of North Florida - Southpoint
    Registry record
    NCT06472245 · updated
  6. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Florida ( Site 0014)
    Registry record
    NCT06312137 · updated
  7. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated
  8. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
    Registry record
    NCT06170788 · updated
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Baptist Medical Center Jacksonville
    Registry record
    NCT06712316 · updated
  10. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Study sites
    21st Century Oncology of Jacksonville - North Lee Street · Cancer Specialists of North Florida - Southpoint
    Registry record
    NCT04613596 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Jacksonville

  1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077)
    Registry record
    NCT06925737 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Melanoma studies recruiting in Jacksonville

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Mayo Clinic Florida
    Registry record
    NCT06246916 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Jacksonville

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Florida
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    Mayo Clinic - Florida
    Registry record
    NCT05303519 · updated
  3. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Mayo Clinic in Florida
    Registry record
    NCT06724237 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mayo Clinic in Florida · Nemours Children's Clinic-Jacksonville
    Registry record
    NCT05675410 · updated
  5. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Baptist Md Anderson Cancer Center
    Registry record
    NCT06846671 · updated
  6. A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Mayo Clinic Jacksonville
    Registry record
    NCT06091865 · updated
  7. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT07188558 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Jacksonville

  1. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT07621718 · updated
  2. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT07805954 · updated
  3. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Baptist MD Anderson Cancer Institute
    Registry record
    NCT07409272 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Ask about studies near Jacksonville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call